Literature DB >> 25480859

Decreased Dicer expression is linked to increased expression of co-stimulatory molecule CD80 on B cells in multiple sclerosis.

Latt Latt Aung1, Konstantin E Balashov2.   

Abstract

BACKGROUND: Multiple sclerosis (MS) is an immune-mediated inflammatory disease of the central nervous system. B cells have been strongly implicated in disease pathogenesis based on clinical trials with B-cell ablation. There is a growing body of evidence linking microRNAs with regulation of the immune system. Dicer, a key enzyme involved in microRNA biogenesis, is necessary for normal B-cell function.
OBJECTIVE: We aimed to determine whether Dicer expression is impaired in B cells and is linked to increased expression co-stimulatory molecules in patients with MS.
METHODS: B cells were separated from blood samples of MS patients and healthy subjects. Expression of Dicer and co-stimulatory molecules CD80 and CD86 was tested. The effect of Dicer modulation on CD80 and CD86 expression in B cells was studied.
RESULTS: Dicer expression was decreased in B cells but not in monocytes of patients with MS compared with healthy subjects. CD80 and CD86 expression was increased on B cells of MS patients compared with healthy subjects. Inhibition of Dicer expression in B cells by small interfering RNA led to increased expression of CD80.
CONCLUSION: Dicer expression is decreased and is mechanistically linked to increased expression of co-stimulatory molecule CD80 in B cells of patients with MS. This may contribute to activation of immune responses in MS.
© The Author(s), 2014.

Entities:  

Keywords:  B cells; CD80; Dicer; Multiple sclerosis

Mesh:

Substances:

Year:  2014        PMID: 25480859      PMCID: PMC4457720          DOI: 10.1177/1352458514560923

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  33 in total

Review 1.  The B7-CD28 superfamily.

Authors:  Arlene H Sharpe; Gordon J Freeman
Journal:  Nat Rev Immunol       Date:  2002-02       Impact factor: 53.106

2.  Immunological memory: contribution of memory B cells expressing costimulatory molecules in the resting state.

Authors:  A Bar-Or; E M Oliveira; D E Anderson; J I Krieger; M Duddy; K C O'Connor; D A Hafler
Journal:  J Immunol       Date:  2001-11-15       Impact factor: 5.422

Review 3.  MicroRNAs: genomics, biogenesis, mechanism, and function.

Authors:  David P Bartel
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

4.  Differential requirements for expression of CD80/86 and CD40 on B cells for T-dependent antibody responses in vivo.

Authors:  Joanne M Lumsden; Joy A Williams; Richard J Hodes
Journal:  J Immunol       Date:  2003-01-15       Impact factor: 5.422

Review 5.  MS and the B cell controversy.

Authors:  Anne H Cross; Emmanuelle Waubant
Journal:  Biochim Biophys Acta       Date:  2010-07-30

6.  Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.

Authors:  Ludwig Kappos; David Li; Peter A Calabresi; Paul O'Connor; Amit Bar-Or; Frederik Barkhof; Ming Yin; David Leppert; Robert Glanzman; Jeroen Tinbergen; Stephen L Hauser
Journal:  Lancet       Date:  2011-10-31       Impact factor: 79.321

7.  Interferon-β inhibits toll-like receptor 9 processing in multiple sclerosis.

Authors:  Konstantin E Balashov; Latt Latt Aung; Adi Vaknin-Dembinsky; Suhayl Dhib-Jalbut; Howard L Weiner
Journal:  Ann Neurol       Date:  2010-12       Impact factor: 10.422

8.  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910

9.  MicroRNAs prevent the generation of autoreactive antibodies.

Authors:  Laura Belver; Virginia G de Yébenes; Almudena R Ramiro
Journal:  Immunity       Date:  2010-11-24       Impact factor: 31.745

10.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

View more
  17 in total

Review 1.  Monoclonal antibodies in the treatment of multiple sclerosis: emergence of B-cell-targeted therapies.

Authors:  Ai-Lan Nguyen; Melissa Gresle; Tessa Marshall; Helmut Butzkueven; Judith Field
Journal:  Br J Pharmacol       Date:  2017-04-26       Impact factor: 8.739

Review 2.  B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence.

Authors:  Silke Kinzel; Martin S Weber
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

3.  Dicer and microRNA expression in multiple sclerosis and response to interferon therapy.

Authors:  William J Magner; Bianca Weinstock-Guttman; Mina Rho; David Hojnacki; Rabia Ghazi; Murali Ramanathan; Thomas B Tomasi
Journal:  J Neuroimmunol       Date:  2016-01-21       Impact factor: 3.478

4.  Epidermal growth factor receptor and B7-H3 expression in esophageal squamous tissues correlate to patient prognosis.

Authors:  Jianxiang Song; Woda Shi; Yajun Zhang; Mingzhong Sun; Xiaodong Liang; Shiying Zheng
Journal:  Onco Targets Ther       Date:  2016-10-12       Impact factor: 4.147

5.  Activation of human B cells negatively regulates TGF-β1 production.

Authors:  Nicolas Molnarfi; Kristbjörg Bjarnadóttir; Mahdia Benkhoucha; Catherine Juillard; Patrice H Lalive
Journal:  J Neuroinflammation       Date:  2017-01-19       Impact factor: 8.322

6.  The modulation of Dicer regulates tumor immunogenicity in melanoma.

Authors:  Nicholas C Hoffend; William J Magner; Thomas B Tomasi
Journal:  Oncotarget       Date:  2016-07-26

Review 7.  Deciphering the Role of B Cells in Multiple Sclerosis-Towards Specific Targeting of Pathogenic Function.

Authors:  Klaus Lehmann-Horn; Silke Kinzel; Martin S Weber
Journal:  Int J Mol Sci       Date:  2017-09-23       Impact factor: 5.923

Review 8.  The Role of MicroRNAs in Repair Processes in Multiple Sclerosis.

Authors:  Conor P Duffy; Claire E McCoy
Journal:  Cells       Date:  2020-07-16       Impact factor: 6.600

Review 9.  B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions.

Authors:  Nele Claes; Judith Fraussen; Piet Stinissen; Raymond Hupperts; Veerle Somers
Journal:  Front Immunol       Date:  2015-12-21       Impact factor: 7.561

Review 10.  Emerging Role of Follicular T Helper Cells in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis.

Authors:  James L Quinn; Robert C Axtell
Journal:  Int J Mol Sci       Date:  2018-10-19       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.